Journal
ACS NANO
Volume 14, Issue 7, Pages 7760-7782Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.0c04006
Keywords
coronavirus disease 2019; severe acute respiratory syndrome coronavirus 2 structure; immunopathology; nanomedicine; targeted therapeutics; combination drug delivery; vaccine nanocarriers; vaccine adjuvant nanoparticles; repurposed nanotechnology
Categories
Funding
- Nano-Sensors and Devices Research Group at Tecnologico de Monterrey [0020209I06]
- Federico Baur Endowed Chair in Nanotechnology [0020240I03]
- CONACYT [SNI 898832, SNI 31803]
Ask authors/readers for more resources
The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this virus nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available